Genetix Pharmaceuticals, Inc.
Genetix is a gene therapy company with a cutting edge gene transfer technology platform (LentiPak™) for the effective therapeutic human delivery of corrective genes for genetic blood disorders and severe chronic human diseases. The Company's lead product, LentiGlobin™, is in Phase I trials for hemoglobin gene therapy in sickle cell disease and beta-thalassemia. EHCP co-led the latest round of financing together with Techno Venture Management and ABN AMRO Ventures.